Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 19, 2025 08:30 ET | Source: HCW Biologics Inc.

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

MIRAMAR, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and...
November 18, 2025 07:25 ET | Source: HCW Biologics Inc.

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions...
November 14, 2025 16:44 ET | Source: HCW Biologics Inc.

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
November 10, 2025 07:00 ET | Source: HCW Biologics Inc.

HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer

MIRAMAR, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering...
November 07, 2025 07:00 ET | Source: HCW Biologics Inc.

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

MIRAMAR, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering...
October 22, 2025 09:00 ET | Source: HCW Biologics Inc.

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment

Watch the "What This Means" video here Featuring the Company’s pembrolizumab-based immune checkpoint inhibitor MIRAMAR, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”...
October 16, 2025 09:25 ET | Source: HCW Biologics Inc.

HCW Biologics to Participate in the 2025 Maxim Growth Summit

MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing...
October 16, 2025 09:15 ET | Source: HCW Biologics Inc.

HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer

MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and...
September 30, 2025 08:45 ET | Source: HCW Biologics Inc.

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

Watch the "What This Means" video here Featuring Company’s second-generation T-Cell Engager program and advantages over first-generation Company’s T-Cell Engager program has made improvements in...
September 18, 2025 09:15 ET | Source: HCW Biologics Inc.

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Wugen closed a $115 million equity financing led by Fidelity Management & Research Company HCW Biologics holds a minority equity interest in Wugen MIRAMAR, Fla., Sept. 18, 2025 (GLOBE...